USSignal de tendance
4
mentions (7j)
4
mentions (30j)
19 mai 2026
premier signal
1
pays concernés
Contexte et analyse
Cette tendance "Huntington's disease therapies under investigation in 2026 pipeline" a été détectée dans la catégorie Santé & Médecine avec un score de 98/100. Cette tendance connaît une croissance explosive et attire beaucoup d'attention actuellement.
Entités liées
Extraits des sources
Consent to Cookies & Data processing We use cookies in accordance with our privacy policy linked below to process end device information and personal data. This serves the integration of content, external services and elements of third parties, statistical analysis/measurement, personalized advertising as well as the integration of social media. Depending on the function, data is thereby passed on to third parties, also in the USA, with the risk of secret access by US authorities and use for...
— openpr.com
Ce que disent les sources
"DelveInsight's 2026 report outlines investigational therapies, clinical trial milestones, and development progress for Huntington's disease treatments."
"The American Society for Gene and Cell Therapy (ASGCT) CEO David Barrett, JD, noted there has been “a nice uptick” in Q1 in start-up funding compared to the..."
"In early May 2026, PTC Therapeutics reported first-quarter revenue of US$272.55 million versus US$1.18 billion a year earlier, swinging from net income of..."
"uniQure (QURE) stock dropped over 37% after a mixed earnings report. The FDA rejected their AMT-130 data package for Huntington's disease, recommending a..."